Master of Musical Chairs
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$UAHC looks ready again
They'll wish they held LAMBOS $OMHE
nice grab giddy up $OMHE
GROUND LEVEL OPPORTUNITY HERE $OMHE WILL BE THE TOP MEDICAL CANNABIS PLAY OF 2018 I truly believe that
Pertaining to timelines referenced from official $OWCP shareholder presentations it would seem updates are expected this quarter.. $OMH3 has nothing to do with it other than their coming to market alot faster then $OWCP
$OMHE The pipeline is front-loaded and ready to burst onto the market in 2018 with highly-effective, CBD-containing, analgesics and other products!!
Yea 40 yrs of history and hundreds of years in collective expierence $OMHE
$OMHE The pipeline is front-loaded and ready to burst onto the market in 2018 with highly-effective, CBD-containing, analgesics and other products that will FIRST be available OVER THE COUNTER!! $OMHE will then use that immediate revenue ready in 2018 to FAST TRACK FDA trial with orphan drug designation to develop prescription CBD based pain relievers BILLION DOLLAR MARKET CAP COMING
Ignorance is a bliss to some I guess $OWCP i know what I hold here BEST IN CLASS cannabis research team and IP portfolio .. pipeline is packed for years to come .. BILLION DOLLAR MARKET CAP POTENTIAL
$OWCP ITS CLOSE TO THE TIME OF MAJOR UPDATES
$OMHE 1 in a million or billion OTC stock
M-O-D has obviously never heard of the try it before you buy it method of sales lmfaoooooooo $OMHE has the perfect game plan SELL OVER THE COUNTER LEGAL CBD products and infused associated OTC products first then develop a fast track FDA designation via orphan drug designation for pain relief that will be so well received by the industry due to Government push to fight Opioids SALES WILL POUR IN and the best part we use the revenue from the Over the Counter sales to fund the FDA process
The pipeline is front-loaded and ready to burst onto the market in 2018 with highly-effective, CBD-containing, analgesics and other products!! the plan is to roll out OTC (over the counter like cosmetics , creams, etc) products first in cannabis friendly markets like Cali, CO, Canada? Use that revenue to then fund FDA trials for prescription based cannabis medicine, BILLION DOLLAR COMPANY IN THE MAKING HERE BOYS AND GIRLS $OMHE
$OMHE bigger then everyone except Goodibag ever imagined The pipeline is front-loaded and ready to burst onto the market in 2018 with highly-effective, CBD-containing, analgesics and other products!!
$OMHE ENOUGH SAID OH YEAHHHHHHHHHHHHHHHHHHHHHHHHH
yes yes yes $OMHE is that stock
I am expecting much more to be added into projections including those stemming from Cosmetics $OMHE MONSTER IN THE MAKING AND NO ONE IS EVEN TALKING ABOUT IT
I know those are a part of the unrestricted shares I mentioned wish you nothing but success $OMHE
Maybe if he actually talked about $OWCP I would like or share his tweets but he hasn't talked about $OWCP in a long time
Unrestricted shares is a tad over 300m but 75m shares of that is owned by $MCIG so free trading 225m but over majority of that is held tightly by a core of whales non flippers imho historical volume proves my theory for there's never been a day eith volume over 12m and we moved 40% yesterday on just over 3m shares traded so free trading float has to be very tight it trades like a float under 20m.......
OMHE Security Details
Share Structure
Market Value1 $35,185,949 a/o Dec 05, 2017
Authorized Shares 2,000,000,000 a/o Nov 30, 2017
Outstanding Shares 982,847,741 a/o Nov 30, 2017
-Restricted 658,009,833 a/o Nov 30, 2017
-Unrestricted 324,837,908 a/o Nov 30, 2017
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
ClearTrust, LLC
Shareholders
$OMHE ONLY MILLIONAIRES HAVE ELEVATORS
Wonder when he hear more about our European Joint Venture $OMHE should hit .07+ on the next update Dollarland can come fast once we get over .10
lots of 5 digit trades on $OMHE that is not retail that is market makers swapping positions between each other getting ready for the massive run up .. DOLLARLAND COMING $OMHE
its cute how your imagination works $OMHE
It unfortunately worked for now.... $omhe
yesterdays news was the tip of an iceberg imho $OMHE has many more announcements and related developments to share
2/9/2018 Malecon Pharma 44th year anniversary $OMHE got big plans for that date
I'm going this year $OWCP I'll take a list of questions from the board to discuss with the team that attends.. I'm looking forward it.. DM me your questions, find me on Twitter @8kraken8 if you don't have PM on here God Bless
Exactly.. nice observations $omhe
amazing day $OMHE see you all tomorrow #blessup
Imagine what 10,000,000+ shares traded will do to PPS $OMHE this trades like a float <20m shares if 3m shares traded increases price by 40% as PPS rises and shares tightly held this will continue higher on less volume OH MY WE GOT OURSELVES A JUICER
BLESSED AND GRATEFUL!!!!! $OMHE
AMAZING STRENGTH HERE $OMHE ABOUT TO CLEAR MAJOR RESISTENCE !
its a literal land grab right now in the medical cannabis industry early adapters like $OMHE will be GREAT SUCCESS
$OMHE NEWs They ARE DEVELOPING 2 STREAMS OF CREAMS ONE FOR FDA DESIGNATION AND THE OTHER FOR OVER THE COUNTER!!!!!!!!
MIAMI, FL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Omni Health, Inc., (OTC: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and biotech engineering, today announced its plan already in motion to create a drug candidate compelling to Big Pharma.
#1 FDA
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
“By employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development,” said Omni Health’s CEO, Andrey Soloviev. “Our projections set this target date at roughly three years out. It will be a strong competitor in a lucrative medicinal niche populated by a limited number of pain management products at exponentially higher valuations. Peer analysis shows these valuations to be in the range of $100 Million to $140 Million.”
#2 OVER THE COUNTER - Additionally, Omni Health is in the final stages of development of non-prescription CBD analgesic creams and ointments with fast absorption properties which we are able to rapidly deploy to the market.
Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles. Given the potency of these analgesics, they will be marketed and distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate patient support and product usage. As per the current schedule, it’s anticipated they this product will be introduced to the North American market during Q3 2018. Based on current market trends and competitor analysis, Omni Health projects generating a recurring annual revenue exceeding $7 Million.
“The Global Market for Pain Management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022 and the Cannabidiol (CBD) market is estimated to grow by 700% by 2020”, concluded Andrey Soloviev, “As such, there is a unique potential for Omni Health to truly seize the day by bringing the first FDA registered CBD pain analgesic to the market”
$OMHE NEWs They ARE DEVELOPING 2 STREAMS OF CREAMS ONE FOR FDA DESIGNATION AND THE OTHER FOR OVER THE COUNTER!!!!!!!!
MIAMI, FL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Omni Health, Inc., (OTC: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and biotech engineering, today announced its plan already in motion to create a drug candidate compelling to Big Pharma.
#1 FDA
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
“By employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development,” said Omni Health’s CEO, Andrey Soloviev. “Our projections set this target date at roughly three years out. It will be a strong competitor in a lucrative medicinal niche populated by a limited number of pain management products at exponentially higher valuations. Peer analysis shows these valuations to be in the range of $100 Million to $140 Million.”
#2 OVER THE COUNTER - Additionally, Omni Health is in the final stages of development of non-prescription CBD analgesic creams and ointments with fast absorption properties which we are able to rapidly deploy to the market.
Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles. Given the potency of these analgesics, they will be marketed and distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate patient support and product usage. As per the current schedule, it’s anticipated they this product will be introduced to the North American market during Q3 2018. Based on current market trends and competitor analysis, Omni Health projects generating a recurring annual revenue exceeding $7 Million.
“The Global Market for Pain Management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022 and the Cannabidiol (CBD) market is estimated to grow by 700% by 2020”, concluded Andrey Soloviev, “As such, there is a unique potential for Omni Health to truly seize the day by bringing the first FDA registered CBD pain analgesic to the market”
$OWCP looks like more are jumping into this topical crème game see link below
https://www.otcmarkets.com/stock/OMHE/news/Omni-Health-Announced-Development-of-New-Drug-Candidate?id=177162&b=y
READ CAREFULLY USE YOUR FINGER TO GUIDE YOU UNDER THE WORDS!!!!!!! THEY ARE DEVELOPING 2 STREAMS OF CREAMS ONE FOR FDA DESIGNATION AND THE OTHER FOR OVER THE COUNTER!!!!!!!!
MIAMI, FL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Omni Health, Inc., (OTC: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and biotech engineering, today announced its plan already in motion to create a drug candidate compelling to Big Pharma.
#1 FDA
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
“By employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development,” said Omni Health’s CEO, Andrey Soloviev. “Our projections set this target date at roughly three years out. It will be a strong competitor in a lucrative medicinal niche populated by a limited number of pain management products at exponentially higher valuations. Peer analysis shows these valuations to be in the range of $100 Million to $140 Million.”
#2 OVER THE COUNTER - Additionally, Omni Health is in the final stages of development of non-prescription CBD analgesic creams and ointments with fast absorption properties which we are able to rapidly deploy to the market.
Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles. Given the potency of these analgesics, they will be marketed and distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate patient support and product usage. As per the current schedule, it’s anticipated they this product will be introduced to the North American market during Q3 2018. Based on current market trends and competitor analysis, Omni Health projects generating a recurring annual revenue exceeding $7 Million.
“The Global Market for Pain Management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022 and the Cannabidiol (CBD) market is estimated to grow by 700% by 2020”, concluded Andrey Soloviev, “As such, there is a unique potential for Omni Health to truly seize the day by bringing the first FDA registered CBD pain analgesic to the market”
Additionally, Omni Health is in the final stages of development of non-prescription CBD analgesic creams and ointments with fast absorption properties which we are able to rapidly deploy to the market.
Simultaneous to the FDA application for this new drug, the Company will commence by manufacturing OTC analgesic creams and ointments containing CBD with rapid absorption and optimal bioavailability profiles. Given the potency of these analgesics, they will be marketed and distributed exclusively to doctors’ offices, clinics, and hospitals to ensure appropriate patient support and product usage. As per the current schedule, it’s anticipated they this product will be introduced to the North American market during Q3 2018. Based on current market trends and competitor analysis, Omni Health projects generating a recurring annual revenue exceeding $7 Million.
“The Global Market for Pain Management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022 and the Cannabidiol (CBD) market is estimated to grow by 700% by 2020”, concluded Andrey Soloviev, “As such, there is a unique potential for Omni Health to truly seize the day by bringing the first FDA registered CBD pain analgesic to the market”
Yes! Great to see you here Kairos
would love to see it open right here churn and burn the .03 and have .03 as our new MEGA SUPPORT!!!!!!!!!! $OMHE throw the PPS projections out the window this has the sky as a limit!!!!!!!!!!!!1